In the first episode of ROP's speaker series we talk to Jesse Hudson. Jesse is the CLO of Woven Science and is working on a policy paper and the release of El Puente. El Puente promotes access and benefit-sharing (ABS) with indigenous peoples and holds 10% of WS's equity. El Puente makes grants and investments in projects owned and operated by indigenous people and has a council of indigenous leaders serving as special advisors to the El Puente board with veto powers in project financing decisions, giving indigenous peoples seats at the table in the growing psychedelics sector.

In The Research Briefing:

- To patent or not to patent psychedelics

- Getting psychedelics to a community clinic near you

- The influence of cannabis on psychedelic experiences

This weeks briefing stories:

1. A new Canadian Research Center.

2. Compass Pathways gets a new patent.

3. Wavepaths is making AI auditory landscapes.

4. A new joint venture appears.

5. Boris Johnson gets psyched.

In The Research Briefing:

- A summary of what we know about 5-MeO-DMT

- Investigating ketamine's chemical structure for safety and efficacy

- Testing how LSD works in the brain by modelling the effects in a whole-brain simulation

In The Briefing:

-Is the success of ketamine a leading industry indicator

-Psychedelics and Music

-Cannabis Global opens research facility

-Mike Tyson Punches In

-An updated Market outlook

In this Episode:

-Delix raises $70M.

-Raves get reviewed.

-What makes a psychedelic?

-A digital therapeutic update.

-Are DNA kits the path forward for psychedelics?

In this weeks briefing:

1. The Trailblazing Unicorn and Psychedelics 2.0?

2. Taking a Trip to ETFs

3. Lifting up Canada’s Psychedelics Industry

4. Psychedelic Medicine and its Impact on Mental Health

5. The New Psychedelic Generation

In this weeks briefing:

-Hamilton Morris joins COMPASS Pathways advisory group.

-Journey Colab gets $12M in funding for mescaline trials.

-Octarine and Clerkenwell partner for clinical trials.

-Mount Sinai gets a $5M grant for psychotherapy training.

-Wesana Health acquires PsyTech.

In this week’s briefing:

Psychedelics increase the size and density of neurons in mouse brains. 

A market update - the reason psychedelics may be attracting smart capital. 

Synthesis Institute raises money in a non-traditional way.  

California is experimenting with microdosing parties. 

Vermont may be the next domino to fall in the medicinal legalization market.

In this week’s briefing:

Transdermal Delivery Methods. 

Music in psychedelics. 

TRIPP acquires PsyAssist  

UW-Madison Research Center

Silo Advances Their Patent Portfolio